ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

AD-233B

A development code.

Its studies are mostly in Diabetes Mellitus, Type 2, led by Yuhan.

Furthest: phase 3, since Sep 7, 20261 company-led study, 1 open or runningNext primary completion: Jun 30, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Yuhan11 open or runningphase 3since Sep 7, 2026Sep 7, 2026Jun 30, 2028phase 3 · NCT07816198

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2026First study: phase 3 study in Diabetes Mellitus, Type 2First studyNCT07816198 · 354 planned

Ahead

  1. Jun 30, 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07816198

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07816198Diabetes Mellitus, Type 23Not yet recruitingJun 30, 2028354

How it is read

Names in the registry

  • “AD-233B”, 1 entry

Codes read as this program: AD233B.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.